Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000147730 | SCV001712000 | pathogenic | Pitt-Hopkins syndrome | 2024-02-23 | reviewed by expert panel | curation | The p.Ser330= variant in TCF4 is absent from gnomAD v4 (PM2_supporting). Splice prediction analysis using multiple computational tools suggests an impact to splicing (PP3). The p.Ser330= variant has been observed in at least 2 individuals with intellectual disability/autism (PMIDs: 29695756, 25693842) (PS4_supporting). The p.Ser330= variant in TCF4 has been reported as a de novo occurrence (biological parentage unconfirmed) in an individual with intellectual disability (PMID: 25693842, internal database -Invitae) (PM6). The p.Ser330= variant in TCF4 has been reported as a de novo occurrence (biological parentage confirmed) in at least 3 individuals with intellectual disability/autism (PMIDs: 29695756, 29158550, 31785789, 1981491, 33767182, internal database - Invitae) (PS2_very strong). In summary, the p.Ser330= variant in TCF4 is classified as pathogenic for Pitt-Hopkins syndrome based on the ACMG/AMP criteria (PM2_supporting, PP3, PS4_supporting, PM6, PS2_very strong). |
Genetic Services Laboratory, |
RCV000147730 | SCV000195195 | likely pathogenic | Pitt-Hopkins syndrome | 2014-02-20 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV000147730 | SCV000586709 | pathogenic | Pitt-Hopkins syndrome | 2017-08-01 | criteria provided, single submitter | clinical testing | De novo variant at the last nucleotide position in gxon 13 of the TCF4 gene in a patient with hypotonia and developmental delay. This Variant has been previously reported as de novo (PMID22495309) in a patient with ID. In house splicing assays showed aberrant splicing. The variant is thus scored as pathogenic (ACMG class 5). |
Gene |
RCV000521305 | SCV000616931 | pathogenic | not provided | 2022-08-28 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; This variant is associated with the following publications: (PMID: 25693842, 29695756, 33767182, 28191890, 22495309, 25780760, 32579932, 27694994, 31785789, 29158550, 32369273, 31069529, 31981491) |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000147730 | SCV003844864 | pathogenic | Pitt-Hopkins syndrome | 2023-02-16 | criteria provided, single submitter | clinical testing | Variant summary: TCF4 c.990G>A (p.Ser330Ser) alters the non-conserved last nucleotide of exon 12 and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Three predict the variant abolishes a 5' splicing donor site. One submitter via Clinvar stated that an in house splicing assay showed aberrant splicing, however did not provide supporting data (Institute of Human Genetics, FAU Erlangen, Friedrich-Alexander-Universitt Erlangen-Nrnberg). The variant was absent in 250940 control chromosomes. c.990G>A has been reported in the literature in individuals affected with Pitt-Hopkins Syndrome, autism spectrum disorder, intellectual disabilities, and neurodevelopmental disorders, including multiple affected individuals in which the variant was de novo (e.g., Geoffrey_2015, Tan_2016, Popp_2017, Mary_2018, Turner_2019, Satterstrom_2020, Martinez-Granero_2021). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported in the literature. Three ClinVar submitters (evaluation after 2014) have cited the variant, and all laboratories classified the variant as pathogenic (n = 2) or likely pathogenic (n = 1). Based on the evidence outlined above, the variant was classified as pathogenic. |
Ce |
RCV000521305 | SCV004010982 | likely pathogenic | not provided | 2023-04-01 | criteria provided, single submitter | clinical testing | TCF4: PS2, PM2:Supporting, PP3, PS4:Supporting |
Institute for Clinical Genetics, |
RCV000521305 | SCV004026398 | pathogenic | not provided | 2023-05-19 | criteria provided, single submitter | clinical testing | PS4, PP3, PM2_SUP |